AVE Science & Technology Co

AVE Science & Technology Co Receivables

The Accounts Receivable of AVE Science & Technology Co (688067.SS) as of Oct 21, 2026 is 5.52 M CNY. In the previous year, Accounts Receivable was 6.35 M CNY — a change of -13.17% (lower).

Receivables

5.52 MCNY

YoY

-13.17%

Last updated:

Accounts Receivable of AVE Science & Technology Co is 2024 5.52 M CNY. Accounts Receivable of AVE Science & Technology Co was 2023 6.35 M CNY. It decreases by -13.17% lower compared to the previous year.

The AVE Science & Technology Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
11.20 M CNY
Jan 1, 2019
11.60 M CNY
Jan 1, 2020
10.30 M CNY
Jan 1, 2021
9.80 M CNY
Jan 1, 2022
7.80 M CNY
Jan 1, 2023
6.35 M CNY
Jan 1, 2024
5.52 M CNY
The AVE Science & Technology Co Receivables history
YEARReceivablesYoY
5.52 MCNY-13.17%
6.35 MCNY-18.55%
7.80 MCNY-20.42%
9.80 MCNY-4.85%
10.30 MCNY-11.21%
11.60 MCNY+3.57%
11.20 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

Accounts Receivable of AVE Science & Technology Co is 5.52 M CNY in 2024.

Accounts Receivable of AVE Science & Technology Co changed from 6.35 M CNY to 5.52 M CNY, representing a -13.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's AVE Science & Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co